Immune effects of mesenchymal stem cells: Implications for Charcot-Marie-Tooth disease

Cellular Immunology

Volumn 253, Issue 1-2, 2008, Pages 11-15

  Leal, Alejandro ^a   Ichim, Thomas E ^b   Marleau, Annette M ^c   Lara, Fabian ^b   Kaushal, Shalesh ^d   Riordan, Neil H ^b  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^b MediStem Laboratories Inc   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Charcot Marie Tooth disease; Immune Modulation; Mesenchymal stem cells; Peripheral neuropathy; Stem cell therapy

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6;

CELL TYPE; CELLULAR DISTRIBUTION; CLINICAL FEATURE; DEMYELINATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMYELINIZATION; REVIEW;

ANIMALS; CHARCOT-MARIE-TOOTH DISEASE; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNITY, NATURAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; TISSUE THERAPY;

EID: 51649128503     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.06.003     Document Type: Review

References (75)

1. Friedenstein A.J., Petrakova K.V., Kurolesova A.I., and Frolova G.P. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6 (1968) 230-247
2. Le Blanc K., and Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J. Intern. Med. 262 (2007) 509-525
3. Schultz S.S., Abraham S., and Lucas P.A. Stem cells isolated from adult rat muscle differentiate across all three dermal lineages. Wound Repair Regen. 14 (2006) 224-231
4. Meng X., Ichim T.E., Zhong J., Rogers A., Yin Z., Jackson J., Wang H., Ge W., Bogin V., Chan K.W., Thebaud B., and Riordan N.H. Endometrial regenerative cells: a novel stem cell population. J. Transl. Med. 5 (2007) 57
5. Bieback K., and Kluter H. Mesenchymal stromal cells from umbilical cord blood. Curr. Stem Cell Res. Ther. 2 (2007) 310-323
6. M. Liu, Z.C. Han, Mesenchymal stem cells: Biology and clinical potential in Type 1 Diabetes Therapy, J Cell Mol Med (2008).
7. Jackson L., Jones D.R., Scotting P., and Sottile V. Adult mesenchymal stem cells: differentiation potential and therapeutic applications. J. Postgrad. Med. 53 (2007) 121-127
8. Keating A. Mesenchymal stromal cells. Curr. Opin. Hematol. 13 (2006) 419-425
9. Verfaillie C.M. Multipotent adult progenitor cells: an update. Novartis Found Symp. 265 (2005) 55-61 discussion 61-5, 92-97
10. Serafini M., Dylla S.J., Oki M., Heremans Y., Tolar J., Jiang Y., Buckley S.M., Pelacho B., Burns T.C., Frommer S., Rossi D.J., Bryder D., Panoskaltsis-Mortari A., O'Shaughnessy M.J., Nelson-Holte M., Fine G.C., Weissman I.L., Blazar B.R., and Verfaillie C.M. Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells. J. Exp. Med. 204 (2007) 129-139
11. Nasef A., Mathieu N., Chapel A., Frick J., Francois S., Mazurier C., Boutarfa A., Bouchet S., Gorin N.C., Thierry D., and Fouillard L. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84 (2007) 231-237
12. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
13. Ryan J.M., Barry F.P., Murphy J.M., and Mahon B.P. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (Lond) 2 (2005) 8
14. Romieu-Mourez R., Francois M., Boivin M.N., Stagg J., and Galipeau J. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J. Immunol. 179 (2007) 1549-1558
15. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., Rouas-Freiss N., Carosella E.D., and Deschaseaux F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 + CD25highFOXP3+ regulatory T cells. Stem Cells 26 (2008) 212-222
16. Augello A., Tasso R., Negrini S.M., Cancedda R., and Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56 (2007) 1175-1186
17. Chen L., Zhang W., Yue H., Han Q., Chen B., Shi M., Li J., Li B., You S., Shi Y., and Zhao R.C. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev. 16 (2007) 719-731
18. Yamaguchi M., Nadler S., Lee J.W., and Deeg H.J. Induction of negative regulators of haematopoiesis in human bone marrow cells by HLA-DR cross-linking. Transpl. Immunol. 7 (1999) 159-168
19. Drager A.M., van der Hem K.G., Zevenbergen A., Odding J.H., Huijgens P.C., and Schuurhuis G.J. Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis. Leukemia 13 (1999) 62-69
20. Sato T., Selleri C., Young N.S., and Maciejewski J.P. Hematopoietic inhibition by interferon-gamma is partially mediated through interferon regulatory factor-1. Blood 86 (1995) 3373-3380
21. Gorski J., Chen X., Gendelman M., Yassai M., Krueger A., Tivol E., Logan B., Komorowski R., Vodanovic-Jankovic S., and Drobyski W.R. Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. Blood 109 (2007) 5502-5510
22. Shulman H.M., Kleiner D., Lee S.J., Morton T., Pavletic S.Z., Farmer E., Moresi J.M., Greenson J., Janin A., Martin P.J., McDonald G., Flowers M.E., Turner M., Atkinson J., Lefkowitch J., Washington M.K., Prieto V.G., Kim S.K., Argenyi Z., Diwan A.H., Rashid A., Hiatt K., Couriel D., Schultz K., Hymes S., and Vogelsang G.B. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol. Blood Marrow Transplant 12 (2006) 31-47
23. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., and Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
24. Giordano A., Galderisi U., and Marino I.R. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J. Cell Physiol. 211 (2007) 27-35
25. Taupin P. OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr. Opin. Investig. Drugs 7 (2006) 473-481
26. Uccelli A., Zappia E., Benvenuto F., Frassoni F., and Mancardi G. Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert. Opin. Biol. Ther. 6 (2006) 17-22
27. Sbano P., Cuccia A., Mazzanti B., Urbani S., Giusti B., Lapini I., Rossi L., Abbate R., Marseglia G., Nannetti G., Torricelli F., Miracco C., Bosi A., Fimiani M., and Saccardi R. Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch. Dermatol. Res. 300 (2008) 115-124
28. Zhang W., Qin C., and Zhou Z.M. Mesenchymal stem cells modulate immune responses combined with cyclosporine in a rat renal transplantation model. Transplant Proc. 39 (2007) 3404-3408
29. Ohnishi S., Yanagawa B., Tanaka K., Miyahara Y., Obata H., Kataoka M., Kodama M., Ishibashi-Ueda H., Kangawa K., Kitamura S., and Nagaya N. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J. Mol. Cell Cardiol. 42 (2007) 88-97
30. Shy M.E. Peripheral neuropathies caused by mutations in the myelin protein zero. J. Neurol. Sci. 242 (2006) 55-66
31. Scherer S.S., and Arroyo E.J. Recent progress on the molecular organization of myelinated axons. J. Peripher. Nerv. Syst. 7 (2002) 1-12
32. Hayasaka K., Himoro M., Sato W., Takada G., Uyemura K., Shimizu N., Bird T.D., Conneally P.M., and Chance P.F. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat. Genet. 5 (1993) 31-34
33. Kochanski A. Mutations in the myelin protein zero result in a spectrum of Charcot-Marie-Tooth phenotypes. Acta Myol. 23 (2004) 6-9
34. Giese K.P., Martini R., Lemke G., Soriano P., and Schachner M. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 71 (1992) 565-576
35. Liu S., Qu Y., Stewart T.J., Howard M.J., Chakrabortty S., Holekamp T.F., and McDonald J.W. Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. Proc. Natl. Acad Sci. USA 97 (2000) 6126-6131
36. Roth T.M., Ramamurthy P., Ebisu F., Lisak R.P., Bealmear B.M., and Barald K.F. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation. Glia 55 (2007) 1123-1133
37. Li L., Baroja M.L., Majumdar A., Chadwick K., Rouleau A., Gallacher L., Ferber I., Lebkowski J., Martin T., Madrenas J., and Bhatia M. Human embryonic stem cells possess immune-privileged properties. Stem Cells 22 (2004) 448-456
38. Nussbaum J., Minami E., Laflamme M.A., Virag J.A., Ware C.B., Masino A., Muskheli V., Pabon L., Reinecke H., and Murry C.E. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 21 (2007) 1345-1357
39. Trzaska K.A., Kuzhikandathil E.V., and Rameshwar P. Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells 25 (2007) 2797-2808
40. Miller R.H., and Bai L. Cellular approaches for stimulating CNS remyelination. Regen. Med. 2 (2007) 817-829
41. Caddick J., Kingham P.J., Gardiner N.J., Wiberg M., and Terenghi G. Phenotypic and functional characteristics of mesenchymal stem cells differentiated along a Schwann cell lineage. Glia 54 (2006) 840-849
42. Zhao F.Q., Zhang P.X., He X.J., Du C., Fu Z.G., Zhang D.Y., and Jiang B.G. Study on the adoption of Schwann cell phenotype by bone marrow stromal cells in vitro and in vivo. Biomed. Environ. Sci. 18 (2005) 326-333
43. Zhang P., He X., Liu K., Zhao F., Fu Z., Zhang D., Zhang Q., and Jiang B. Bone marrow stromal cells differentiated into functional Schwann cells in injured rats sciatic nerve. Artif. Cells Blood Substit. Immobil. Biotechnol. 32 (2004) 509-518
44. Ben-Hur T., Einstein O., and Bulte J.W. Stem cell therapy for myelin diseases. Curr. Drug. Targets. 6 (2005) 3-19
45. Erdem S., Mendell J.R., and Sahenk Z. Fate of Schwann cells in CMT1A and HNPP: evidence for apoptosis. J. Neuropathol. Exp. Neurol. 57 (1998) 635-642
46. Wang M., Crisostomo P.R., Herring C., Meldrum K.K., and Meldrum D.R. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (2006) R880-R884
47. Gora-Kupilas K., and Josko J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol. 43 (2005) 31-39
48. Machida S., Tanaka M., Ishii T., Ohtaka K., Takahashi T., and Tazawa Y. Neuroprotective effect of hepatocyte growth factor against photoreceptor degeneration in rats. Invest. Ophthalmol. Vis. Sci. 45 (2004) 4174-4182
49. Ying Wang J., Peruzzi F., Lassak A., Del Valle L., Radhakrishnan S., Rappaport J., Khalili K., Amini S., and Reiss K. Neuroprotective effects of IGF-I against TNFalpha-induced neuronal damage in HIV-associated dementia. Virology 305 (2003) 66-76
50. Herrera M.B., Bussolati B., Bruno S., Fonsato V., Romanazzi G.M., and Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int. J. Mol. Med. 14 (2004) 1035-1041
51. Krause U., Harter C., Seckinger A., Wolf D., Reinhard A., Bea F., Dengler T., Hardt S., Ho A., Katus H.A., Kuecherer H., and Hansen A. Intravenous delivery of autologous mesenchymal stem cells limits infarct size and improves left ventricular function in the infarcted porcine heart. Stem Cells Dev. 16 (2007) 31-37
52. Nagaya N., Fujii T., Iwase T., Ohgushi H., Itoh T., Uematsu M., Yamagishi M., Mori H., Kangawa K., and Kitamura S. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H2670-H2676
53. Sykova E., and Jendelova P. In vivo tracking of stem cells in brain and spinal cord injury. Prog. Brain Res. 161 (2007) 367-383
54. Parr A.M., Tator C.H., and Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant. 40 (2007) 609-619
55. Croitoru-Lamoury J., Lamoury F.M., Zaunders J.J., Veas L.A., and Brew B.J. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J. Interferon Cytokine Res. 27 (2007) 53-64
56. Herrera M.B., Bussolati B., Bruno S., Morando L., Mauriello-Romanazzi G., Sanavio F., Stamenkovic I., Biancone L., and Camussi G. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 72 (2007) 430-441
57. Schmidt B., Toyka K.V., Kiefer R., Full J., Hartung H.P., and Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19 (1996) 474-487
58. Young P., and Suter U. Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease. Brain Res. Brain Res. Rev. 36 (2001) 213-221
59. Shy M.E., Arroyo E., Sladky J., Menichella D., Jiang H., Xu W., Kamholz J., and Scherer S.S. Heterozygous P0 knockout mice develop a peripheral neuropathy that resembles chronic inflammatory demyelinating polyneuropathy (CIDP). J. Neuropathol. Exp. Neurol. 56 (1997) 811-821
60. Maurer M., Kobsar I., Berghoff M., Schmid C.D., Carenini S., and Martini R. Role of immune cells in animal models for inherited neuropathies: facts and visions. J. Anat. 200 (2002) 405-414
61. Kobsar I., Oetke C., Kroner A., Wessig C., Crocker P., and Martini R. Attenuated demyelination in the absence of the macrophage-restricted adhesion molecule sialoadhesin (Siglec-1) in mice heterozygously deficient in P0. Mol. Cell Neurosci. 31 (2006) 685-691
62. Wang Ip C., Kroner A., Fischer S., Berghoff M., Kobsar I., Maurer M., and Martini R. Role of immune cells in animal models for inherited peripheral neuropathies. Neuromolecular Med. 8 (2006) 175-190
63. Kobsar I., Hasenpusch-Theil K., Wessig C., Muller H.W., and Martini R. Evidence for macrophage-mediated myelin disruption in an animal model for Charcot-Marie-Tooth neuropathy type 1A. J. Neurosci. Res. 81 (2005) 857-864
64. Bird S.J., and Sladky J.T. Corticosteroid-responsive dominantly inherited neuropathy in childhood. Neurology 41 (1991) 437-439
65. Dyck P.J., Swanson C.J., Low P.A., Bartleson J.D., and Lambert E.H. Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin. Proc. 57 (1982) 239-246
66. de Ferranti S.D., and Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc. Pathol. 16 (2007) 14-21
67. Xu W., Manichella D., Jiang H., Vallat J.M., Lilien J., Baron P., Scarlato G., Kamholz J., and Shy M.E. Absence of P0 leads to the dysregulation of myelin gene expression and myelin morphogenesis. J. Neurosci. Res. 60 (2000) 714-724
68. Jiang D., Liang J., and Noble P.W. Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol. 23 (2007) 435-461
69. Back S.A., Tuohy T.M., Chen H., Wallingford N., Craig A., Struve J., Luo N.L., Banine F., Liu Y., Chang A., Trapp B.D., Bebo Jr. B.F., Rao M.S., and Sherman L.S. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 11 (2005) 966-972
70. Chandross K.J., Spray D.C., Cohen R.I., Kumar N.M., Kremer M., Dermietzel R., and Kessler J.A. TNF alpha inhibits Schwann cell proliferation, connexin46 expression, and gap junctional communication. Mol. Cell Neurosci. 7 (1996) 479-500
71. Lee P.H., Kim J.W., Bang O.Y., Ahn Y.H., Joo I.S., and Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin. Pharmacol. Ther. 83 (2008) 723-730
72. Bang O.Y., Lee J.S., Lee P.H., and Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann. Neurol. 57 (2005) 874-882
73. Liu L., Sun Z., Chen B., Han Q., Liao L., Jia M., Cao Y., Ma J., Sun Q., Guo M., Liu Z., Ai H., and Zhao R.C. Ex vivo expansion and in vivo infusion of bone marrow-derived Flk-1 + CD34- mesenchymal stem cells: feasibility and safety from monkey to human. Stem Cells Dev. 15 (2006) 349-357
74. Wu Y., Chen L., Scott P.G., and Tredget E.E. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25 (2007) 2648-2659
75. Sahenk Z., Nagaraja H.N., McCracken B.S., King W.M., Freimer M.L., Cedarbaum J.M., and Mendell J.R. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 65 (2005) 681-689